Over the past year, Gilead Sciences‘ (NASDAQ: GILD) shares have steadily marched lower due to the flattening sales of its hep C drug Harvoni.
Over the past year, Gilead Sciences‘ (NASDAQ: GILD) shares have steadily marched lower due to the flattening sales of its hep C drug Harvoni.